| INTRODUCTION
Influenza is a major cause of global morbidity and mortality each year, especially among older adults and those with chronic diseases. 1 Although several statistical models have estimated the mortality burden of influenza, 2 few have focused on mainland China, [3] [4] [5] and information on mortality burden in northern China is especially limited. Considering the diverse seasonality patterns, 6 income levels and healthcare access across China, mortality burden may vary by region.
Beijing, the capital of China, is located in northern China. The copyright line for this article was changed on 25 January 2018 after original online publication 10 844 laboratory-confirmed cases of influenza A(H1N1)pdm09 and 69 deaths were reported in Beijing. 7 These numbers solely represent laboratory-confirmed influenza deaths and not decedents who might have died because of pandemic influenza but were never tested. 3 A mathematical modeling study estimated that the likely number of influenza A (H1N1)pdm09 infections in Beijing was 1.8 million during the pandemic period. 8 To date, no study has estimated the likely number of influenza A(H1N1)pdm09-associated deaths in Beijing.
Since 2007, the Beijing Municipal Government has provided seasonal influenza vaccination to priority populations, including adults ≥60 years of age and primary and middle school students, free of charge between September and November each year prior to the start of typical influenza virus circulation. Beijing also conducted influenza A(H1N1)pdm09 vaccination campaigns during the pandemic period. 9 These programs were implemented in the absence of local data on influenza-associated mortality burden because there was concern that this novel virus could have substantial burden on the population's health. Influenza mortality burden data allow programs to determine the potential impact of influenza vaccination and inform investments in prevention strategies. In this study, we modeled mortality data obtained from a representative mortality register system, combined with weekly influenza virus surveillance data, to provide estimates of the mortality impact associated with seasonal influenza and the influenza A(H1N1)pdm09 virus during the pandemic period by specific death categories, age groups, and influenza virus type and subtype in Beijing from 2007 to 2013.
| METHODS

| Population data
We obtained annual population data from the National Population Census in Beijing, China. 10 In 2010, the total population of Beijing was nearly 20 million, of which 12-13 million were registered residents of Beijing. The remaining 7-8 million persons were classified as "migrants" who are not registered residents of Beijing. In this study, we used population data of registered populations only to calculate the annual mortality rates.
| Mortality data
Local regulation requires that all deaths in Beijing are registered in the Mortality Register and Surveillance System, managed by Beijing
Center for Disease Control and Prevention (BJCDC). We were unable to obtain reliable mortality data among migrants, as both Chinese culture and high medical expenses compel a large proportion of migrants to return to their home provinces when they are severely ill, and therefore, the majority of migrants do not die in Beijing and are not registered in the BJCDC Mortality Register and Surveillance system. In this study, we obtained weekly electronic mortality data respiratory (ICD-10 codes J00-99) and circulatory diseases (ICD-10 codes I00-99) (respiratory and circulatory: R&C), and all-cause deaths (including both respiratory and circulatory deaths which have been previously been associated with influenza-associated deaths).
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Two age groups were considered: <65 years and ≥65 years.
| Influenza virology data
We obtained influenza virology data from the Beijing influenza surveil- 
| Statistical model
A negative binomial model was applied to estimate influenza-associated excess mortality, using age-specific weekly mortality data as the outcome and proportions of specimens positive for influenza by type/subtype (not age-specific) as the predictor variables. Further explanation of our model selection is available in Table S1 .
The number of deaths attributed to influenza was calculated as the difference between the predicted influenza-associated deaths from the full model and the predicted baseline deaths (from the model when the co-variables for influenza subtype were set to zero).
Confidence intervals were generated for excess mortality estimates based on the confidence intervals of the model predictions. Agespecific excess mortality rates were calculated from the estimated number of deaths attributed to influenza divided by population from the National Population Census in Beijing, China. 10 All the statistical analyses were carried out using SAS University Edition (SAS Institute
Inc., Cary, NC, USA). A P value < .05 was considered to be statistically significant.
| Ethics approval
Study approval was obtained from the Institutional Review Board and
Human Research Ethics Committee of BJCDC. persons for all ages and 2050.0 to 2221.0 per 100 000 for adults aged ≥65 years. Adults aged ≥65 years accounted for 84% of R&C deaths among all ages (Table 1 ).
| RESULTS
| Mortality data reported from the Mortality
During the 6-year study period, a total of 60 795 specimens were Table 5 shows comparisons of mortality burden between seasonal epidemics and the influenza A(H1N1)pdm09 pandemic period from this per 100 000). However, the differences did not reach statistical significance (P > .05). Persons aged <65 years represented a greater proportion of all deaths during the influenza A(H1N1)pdm09 pandemic period than during the seasonal epidemics (27.0% vs 17.7%, P < .05).
| Comparisons of mortality burden between seasonal epidemics and the influenza A(H1N1)pdm09 pandemic period
A similar mortality burden age shift toward persons <65 years of age was also observed for respiratory and circulatory deaths. States, 18, 19 and New Zealand, 23 where the highest death rates were associated with influenza A(H3N2). In addition, the highest mortality . 24 The mismatch of Our findings for the all-age mortality burden of seasonal influenza are comparable with previous studies derived from similar approaches in China (Table 5) 3-5 and other areas, such as Hong Kong, 14 Singapore, 16 USA, 18 and Mexico. 20 For adults aged ≥65 years, however, our estimate is lower than previous estimates made for China Beijing may be the higher seasonal influenza vaccine coverage among older adults in Beijing compared with older adults in the rest of China.
| DISCUSSION
Since 2007, the Beijing Municipal Government has provided annual seasonal influenza vaccination to older adults free of charge, and the vaccine coverage rate for this population in season 2010/2011 was 43%. 9 In most regions of China, older adults must pay for the seasonal influenza vaccine out of pocket, leading to very low vaccine coverage.
One study estimated that the vaccine coverage in the Chinese population overall was only 2% in 2009. 27 Second, as the largest proportion of influenza-associated deaths among older adults is among those aged ≥75 years, 18 different age distributions across regions may contribute to differences in influenza-associated mortality burden. Beijing is a large city with a very high population aging rate that has reached the average level of developed countries. 28 A higher proportion of adults aged ≥75 years in Beijing may contribute to a higher mortality burden among all adults aged ≥65 years. However, as Beijing is also one of the most developed regions in China, on average, its residents have higher socioeconomic status and better access to health care than residents in other Chinese regions which, in turn, may contribute to a lower mortality burden among older adults.
We estimated that the all-cause mortality rate associated with influenza A(H1N1)pdm09 was comparable to the mortality impact of seasonal epidemics during the non-pandemic seasons (19.9 vs 17.2 per 100 000). Although the influenza A(H1N1)pdm09 mortality rate in this study is similar to that estimated by another study in China, 4 it is lower than the rate described in Mexico, 20 and higher than rates estimated in the United States. 29 The case fatality rate of pH1N1 infection during the pandemic was higher in Mexico than in Beijing (1.2% vs 0.6%), 30 contributing to the higher influenza A(H1N1)pdm09 mortality rate described in Mexico. Many factors may have contributed to the regional difference in the mortality impact of the pandemic virus between Mexico and Beijing, including epidemic intensity, use of influenza vaccine and antiviral drugs, and healthcare access.
Meanwhile, the lower rates described in the United States may have been associated with the higher vaccination coverage for influenza Consistent with studies conducted in other countries, our study found that, compared with seasonal epidemics, there was an "age shift" in age-specific mortality burden toward persons <65 years of age during the influenza A(H1N1)pdm09 pandemic period. 4, 20, 29, [33] [34] [35] [36] A previous meta-analysis from 27 studies showed that the influenza A(H1N1)pdm09 cumulative incidence varied significantly by age with much higher incidence in younger people. 37 In addition, a study comparing seasonal influenza and influenza A(H1N1)pdm09 demonstrated that younger people had 2-4 times the risk of severe outcomes from influenza A(H1N1)pdm09 than persons of the same ages with seasonal influenza. 38 These findings suggest that prevention and control measures during pandemics may need to target younger adults who are not considered high risk during seasonal epidemics.
This study has several limitations. First, although underreporting of deaths in Beijing is low when compared to China overall (4-7% vs 17%), [39] [40] [41] it is possible that underreporting still led to an underestimation of influenza mortality. Second, because Beijing does not have access to local respiratory syncytial virus (RSV) virology data, we were unable to control for RSV co-circulation. As RSV is associated with substantial mortality, 18 not accounting for RSV may have inflated our influenza-related mortality burden estimate.
While it is possible that our estimates might be an overestimate of influenza-associated deaths, the inclusion of viral surveillance terms T A B L E 5 Comparisons of influenza-associated death rates (per 100 000 persons) by age and death category in this study with previous studies from China significantly reduces the chance of overestimation. Prior to including these terms, we evaluated the surveillance data to ensure that it was robust and did not show instances of bias due to few specimens being collected. We also compared our viral surveillance data to the national system which showed a similar pattern in influenza virus circulation for the northern region of China. Third, we did not have the sample size available to obtain reliable estimates within more refined age categories. There were also several factors that may contribute to deaths in Beijing that we were unable to include in our model, such as air quality, which is particularly poor in Beijing especially when compared to cities outside of China. Finally, our estimates were based on an ecological study design, and therefore, we cannot confirm a causal relationship between influenza activity and our estimates of mortality burden.
| CONCLUSIONS
Our study demonstrates a substantial influenza-related mortal- strategies to increase vaccine coverage in this population at highest risk for seasonal influenza-related mortality. Second, the increased influenza-associated mortality rates among persons <65 years of age during the influenza A(H1N1)pdm09 pandemic period suggest that the most effective pandemic vaccination strategies may differ from those used for seasonal influenza; it is important to identify and vaccinate populations at highest risk for morbidity and mortality during each pandemic.
